<div id="readability-page-1"><p>OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles Berkman sold 8,044 shares of OmniAb stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $1.96, for a total value of $15,766.24. Following the sale, the insider directly owned 377,071 shares of the company's stock, valued at approximately $739,059.16. The trade was a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.</p><h2>OmniAb Price Performance</h2><p>Shares of NASDAQ OABI opened at $1.99 on Tuesday. The firm has a market cap of $286.48 million, a price-to-earnings ratio of -3.43 and a beta of 0.13. The stock's fifty day moving average price is $1.65 and its two-hundred day moving average price is $1.71. OmniAb, Inc. has a one year low of $1.22 and a one year high of $4.17. </p><p>OmniAb (NASDAQ:OABI - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to the consensus estimate of $5.64 million.  On average, equities analysts anticipate that  OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On OmniAb</h2><p>Hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in shares of  OmniAb by 20.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company's stock valued at $78,000 after buying an additional 7,624 shares in the last quarter.  Murchinson Ltd. boosted its position in shares of  OmniAb by 0.8% during the 1st quarter. Murchinson Ltd. now owns 1,007,810 shares of the company's stock worth $2,419,000 after acquiring an additional 7,810 shares in the last quarter.  Rhumbline Advisers increased its stake in  OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company's stock valued at $280,000 after acquiring an additional 9,163 shares during the last quarter.  Osaic Holdings Inc. raised its position in  OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after purchasing an additional 9,716 shares in the last quarter.  Finally, AQR Capital Management LLC acquired a new position in  OmniAb during the first quarter valued at approximately $25,000. 72.08% of the stock is owned by institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of OmniAb in a report on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $6.67.</p><p><b>View Our Latest Analysis on OmniAb</b></p><h2>About OmniAb</h2> (Get Free Report)<p>OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than OmniAb</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li><li>What Are Dividend Achievers? An Introduction</li><li>Top 5 Highest-Rated Dividend Stocks, According to MarketBeat</li><li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in OmniAb Right Now?</h2><p>Before you consider OmniAb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OABI

<p>OmniAb, Inc. insider Charles Berkman sold 8,044 shares at $1.96 each, totaling $15,766.24. Post-sale, Berkman owns 377,071 shares, a 2.09% decrease in ownership. The transaction was disclosed in an SEC filing. OmniAb's stock opened at $1.99 with a market cap of $286.48 million. Analysts have a consensus 'Moderate Buy' rating with a $6.67 price target. The company reported a Q3 loss of $0.14 per share, slightly better than expected.</p>

OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 8,044 Shares